Organ-on-a-Chip Global Market – Forecast To 2026

Publishing Date : April, 2020
Report Code : HCBT0117
Price:
Single license $4,950
Site license $6,750
Global license $9,000


Note: The report would be dispatched after confirmation of payment

Organ-on-a-Chips are AA battery sized microfluidic chips designed accurately to recreate the natural physiology and mechanical forces that cells experience in the human body. Organ-on-a-Chip is gaining popularity as they are rendered crucial for prognosis and monitor disease progression; personalized medicine along with playing a vital role in discovery and development of target molecules and drug toxicity testing also to cut cost and time of drug development.

According to IQ4I Research analysis, the Organ-on-a-Chip global market is estimated to reach $193,316.9 thousand by 2026 growing at a very high double digit CAGR from 2019 to 2026. The Organ-on-a-Chip market is classified into product, application, material type, end-user, and geography.

The factors driving the market are rising use of organ-on-a-chip in early detection of drug toxicity, increasing demand for personalized medicine, emergence of OOC as an alternative to animal testing, the significant increase in research funding and venture capital investments for the development of different types of organ-on-a-chips, whereas, factors such as technical uncertainty within the pharma companies, the lack of scaling and standardization, biological and technical challenges involved are restraining the market growth.

The Organ-on-a-Chip product market is further classified into chips & services. The services segment accounted for the largest revenue in 2019. The Chips market is further segmented into liver, lung, kidney, tumor, multiple-organ-on-a-chip, and others. Among these, liver-on-a-chip accounted for the largest revenue in 2019 and is expected to grow at a strong double digit CAGR from 2019 to 2026. The factors driving the market are increasing use of Liver-on-a-chip in drug discovery as a disease model (NASH) and also in toxicity screening of drugs, cosmetics, environmental pollutants, etc. The growth is also attributed to the increased interest shown by regulatory agencies, by the top pharma companies, other government organizations and venture capitalists for the development of the technology, whereas, factors such as lack of scaling and standards, the uncertainty of how regulatory bodies will adapt to technological changes, as OOC is in its infancy stage, they are still not efficient to replace the current methods followed, but, are used as an additional test for accuracy, complexity in the establishment of organ models, challenge to explore sample associated data requirement of ethical clarity, need for the establishment of well understood single mixed- cell models using universal media combined with the flow and supporting matrix are restraining the market growth.

Based on the application, the market is segmented into drug discovery, toxicity screening, and personalized medicine. Among these toxicity, screening accounted for the largest revenue of in 2019 and is expected to grow at a high double digit CAGR from 2019 to 2026 due to increased failure of drugs due to their toxicity had lead to the accelerated use of organ-on-a-chip involving human-derived cells to check their toxic effects. Further engagement of various chips in environmental toxicity testing, cosmetic toxicity is driving the growth of the market.

The market by material type is segmented into PDMS, polymers, glass, and silicon, among these, polymers commanded the largest revenue in 2019 and is expected to grow at a high double digit CAGR from 2019 to 2026. Factors such as ease of access and inexpensiveness, optically transparent, biocompatible, inert, rigidity are the factors favoring their usage. The silicon segment is expected to grow at a strong CAGR from 2019 to 2026.

Based on End-User, the market is segmented into Pharma & Biotech, Academic & research institutes, and other industries. Among the end-users, Pharma & Biotech accounted for the largest revenue in 2019 growing at a strong double digit CAGR from 2019 to 2026 due to extended research and development activities in biologics, drug development, and manufacturing.

Based on geography, the market is segmented into North America, Europe, Asia-Pacific and the Rest of the world. Among these, the North American region dominated the Organ-On-A-Chip accounted for the largest revenue in 2019 growing at a high double digit CAGR from 2019 to 2026. This is due to the accelerated technological advancements in analytical and informatics field, presence of major players, increased funding from both private and government agencies, growing awareness about benefits of Organ-On-A-Chip in development of personalized medicine, presence of advanced research institutes with specialized technologies, pharma biotech companies, government & private agencies concentrating on accelerating Organ-on-a-Chip research. The Asia-Pacific region is the fastest-growing region with a strong CAGR from 2019 to 2026. This might be attributed to increasing government funding towards Organ-on-a-Chip research, and the emergence of this region as the manufacturing hub for biologics drugs.

Some of the companies are coming up with new technological advancements to maintain their leadership status in the Organ-on-a-Chip, for example, Mimetas BV launched assay ready product line: OrganoPlate Caco-2 which serves customer to receive a fully quality-controlled, ready-to-use tissue model to ADME, safety-, toxicology- and mechanistic studies for drug development, but also in the food and dairy industry.

The key players in Organ-on-a-Chip Global Market include Mimetas BV (The Netherlands), Emulate, Inc. (U.S), TissUse GmbH (Germany), Hesperos, Inc. (U.S.), Insphero AG. (Switzerland), CN Bio Innovations Ltd (U.K.), Nortis Inc ( U.S.), AlveoliX AG (Switzerland), Organovo Holdings, Inc. (U.S.) and others.

The report provides an in-depth market analysis of the above-mentioned segments across the following regions:

  • North America
  • Europe
  • Asia-Pacific 
  • Rest of the World (RoW)
  • 1     EXECUTIVE SUMMARY
  • 2     INTRODUCTION
    • 2.1     KEY TAKEAWAYS
    • 2.2     SCOPE OF THE REPORT
    • 2.3     REPORT DESCRIPTION
    • 2.4     MARKETS COVERED
    • 2.5     STAKEHOLDERS
    • 2.6     RESEARCH METHODOLOGY
      • 2.6.1     MARKET SIZE ESTIMATION
      • 2.6.2     MARKET BREAKDOWN AND DATA TRIANGULATION
      • 2.6.3     SECONDARY SOURCES
      • 2.6.4     PRIMARY SOURCES
      • 2.6.5     KEY DATA POINTS FROM SECONDARY SOURCES
      • 2.6.6     KEY DATA POINTS FROM PRIMARY SOURCES
      • 2.6.7     ASSUMPTIONS
  • 3     MARKET ANALYSIS
    • 3.1     INTRODUCTION
    • 3.2     MARKET SEGMENTATION
    • 3.3     FACTORS INFLUENCING MARKET
      • 3.3.1     DRIVERS AND OPPORTUNITIES
        • 3.3.1.1     NEED FOR EARLY DETECTION OF DRUG TOXICITY
        • 3.3.1.2     INCREASING DEMAND FOR PERSONALIZED MEDICINE
        • 3.3.1.3     EMERGENCE OF OOC AS AN ALTERNATIVE TO ANIMAL TESTING
        • 3.3.1.4     SIGNIFICANT INCREASE IN RESEARCH FUNDING AND VENTURE CAPITAL INVESTMENTS
      • 3.3.2     RESTRAINTS AND THREATS
        • 3.3.2.1     TECHNICAL UNCERTAINTY WITHIN THE PHARMA COMPANIES
        • 3.3.2.2     LACK OF SCALING AND STANDARDIZATION
        • 3.3.2.3     BIOLOGICAL AND TECHNICAL CHALLENGES
    • 3.4     REGULATORY AFFAIRS
      • 3.4.1     UNITED STATES
      • 3.4.2     EUROPE
      • 3.4.3     ASIA-PACIFIC
    • 3.5     TECHNOLOGICAL ADVANCEMENTS
      • 3.5.1     INTRODUCTION
      • 3.5.2     HUMAN ON CHIP (BODY-ON-A-CHIP)
      • 3.5.3     ORGANOID-ON-A-CHIP
      • 3.5.4     PATIENT-ON-A-CHIP
      • 3.5.5     AUTOMATION
      • 3.5.6     ADVANCEMENT IN STEM CELL CULTURE
    • 3.6     PORTER’S FIVE FORCE ANALYSIS
      • 3.6.1     THREAT OF NEW ENTRANTS
      • 3.6.2     THREAT OF SUBSTITUTES
      • 3.6.3     RIVALRY AMONG EXISTING COMPETITORS
      • 3.6.4     BARGAINING POWER OF SUPPLIERS
      • 3.6.5     BARGAINING POWER OF BUYERS
    • 3.7     MARKET SHARE ANALYSIS BY MAJOR PLAYERS
      • 3.7.1     ORGAN-ON-A-CHIP GLOBAL MARKET SHARE ANALYSIS
    • 3.8     ORGAN-ON-A-CHIP UNITS SOLD
  • 4     ORGAN-ON-A-CHIP GLOBAL MARKET, BY PRODUCTS
    • 4.1     INTRODUCTION
    • 4.2     CHIPS
      • 4.2.1     LIVER-ON-A-CHIP
      • 4.2.2     LUNG-ON-A-CHIP
      • 4.2.3     KIDNEY-ON-A-CHIP
      • 4.2.4     TUMOR-ON-A-CHIP
      • 4.2.5     MULTI-ORGAN-ON-A-CHIP
      • 4.2.6     OTHERS
        • 4.2.6.1     NERVE-ON-A-CHIP
        • 4.2.6.2     HEART-ON-A-CHIP
        • 4.2.6.3     SKIN-ON-A-CHIP
        • 4.2.6.4     BLOOD VESSELS-ON-A-CHIP
        • 4.2.6.5     INTESTINE-ON-A-CHIP
        • 4.2.6.6     OTHERS (BLOOD-BRAIN BARRIER-ON-A-CHIP, LYMPHATIC VESSEL-ON-A-CHIP, EYE-ON-A-CHIP)
    • 4.3     SERVICES
  • 5     ORGAN-ON-A-CHIP GLOBAL MARKET, BY MATERIAL TYPE
    • 5.1     INTRODUCTION
    • 5.2     PDMS (POLY-DI-METHYL-SILOXANE)
    • 5.3     POLYMERS
    • 5.4     GLASS
    • 5.5     SILICON
  • 6     ORGAN-ON-A-CHIP GLOBAL MARKET, BY APPLICATION
    • 6.1     INTRODUCTION
    • 6.2     DRUG DISCOVERY
    • 6.3     TOXICITY SCREENING
    • 6.4     PERSONALIZED MEDICINE
  • 7     ORGAN-ON-A-CHIP GLOBAL MARKET, BY END-USERS
    • 7.1     INTRODUCTION
    • 7.2     PHARMA BIOTECH
    • 7.3     ACADEMICS AND RESEARCH INSTITUTES
    • 7.4     OTHER INDUSTRIES
  • 8     ORGAN-ON-A-CHIP GLOBAL MARKET, BY REGION
    • 8.1     INTRODUCTION
    • 8.2     NORTH AMERICA
    • 8.3     EUROPE
    • 8.4     ASIA-PACIFIC
    • 8.5     REST OF THE WORLD
  • 9     COMPETITIVE LANDSCAPE
    • 9.1     INTRODUCTION
    • 9.2     AGREEMENTS AND COLLABORATIONS
    • 9.3     NEW PRODUCT AND SERVICE LAUNCH
    • 9.4     FUNDING
    • 9.5     OTHERS
  • 10     MAJOR COMPANIES
    • 10.1     ALVEOLIX AG
      • 10.1.1     OVERVIEW
      • 10.1.2     FINANCIALS
      • 10.1.3     PRODUCT PORTFOLIO
      • 10.1.4     KEY DEVELOPMENTS
      • 10.1.5     BUSINESS STRATEGY
      • 10.1.6     SWOT ANALYSIS
    • 10.2     CN BIO INNOVATIONS LTD.
      • 10.2.1     OVERVIEW
      • 10.2.2     FINANCIALS
      • 10.2.3     PRODUCT PORTFOLIO
      • 10.2.4     KEY DEVELOPMENTS
      • 10.2.5     BUSINESS STRATEGY
      • 10.2.6     SWOT ANALYSIS
    • 10.3     EMULATE, INC.
      • 10.3.1     OVERVIEW
      • 10.3.2     FINANCIALS
      • 10.3.3     PRODUCT PORTFOLIO
      • 10.3.4     KEY DEVELOPMENTS
      • 10.3.5     BUSINESS STRATEGY
      • 10.3.6     SWOT ANALYSIS
    • 10.4     HESPEROS, INC.
      • 10.4.1     OVERVIEW
      • 10.4.2     FINANCIALS
      • 10.4.3     PRODUCT PORTFOLIO
      • 10.4.4     KEY DEVELOPMENTS
      • 10.4.5     BUSINESS STRATEGY
      • 10.4.6     SWOT ANALYSIS
    • 10.5     INSPHERO AG
      • 10.5.1     OVERVIEW
      • 10.5.2     FINANCIALS
      • 10.5.3     PRODUCT PORTFOLIO
      • 10.5.4     KEY DEVELOPMENTS
      • 10.5.5     BUSINESS STRATEGY
      • 10.5.6     SWOT ANALYSIS
    • 10.6     MIMETAS B.V.
      • 10.6.1     OVERVIEW
      • 10.6.2     FINANCIALS
      • 10.6.3     PRODUCT PORTFOLIO
      • 10.6.4     KEY DEVELOPMENTS
      • 10.6.5     BUSINESS STRATEGY
      • 10.6.6     SWOT ANALYSIS
    • 10.7     NORTIS, INC.
      • 10.7.1     OVERVIEW
      • 10.7.2     FINANCIALS
      • 10.7.3     PRODUCT PORTFOLIO
      • 10.7.4     KEY DEVELOPMENTS
      • 10.7.5     BUSINESS STRATEGY
      • 10.7.6     SWOT ANALYSIS
    • 10.8     ORGANOVO HOLDINGS, INC.
      • 10.8.1     OVERVIEW
      • 10.8.2     FINANCIALS
      • 10.8.3     PRODUCT PORTFOLIO
      • 10.8.4     KEY DEVELOPMENTS
      • 10.8.5     BUSINESS STRATEGY
      • 10.8.6     SWOT ANALYSIS
    • 10.9     SYNVIVO, INC.
      • 10.9.1     OVERVIEW
      • 10.9.2     FINANCIALS
      • 10.9.3     PRODUCT PORTFOLIO
      • 10.9.4     KEY DEVELOPMENTS
      • 10.9.5     BUSINESS STRATEGY
      • 10.9.6     SWOT ANALYSIS
    • 10.10     TARA BIOSYSTEMS, INC.
      • 10.10.1     OVERVIEW
      • 10.10.2     FINANCIALS
      • 10.10.3     PRODUCT PORTFOLIO
      • 10.10.4     KEY DEVELOPMENTS
      • 10.10.5     BUSINESS STRATEGY
      • 10.10.6     SWOT ANALYSIS
    • 10.11     TISSUSE GMBH
      • 10.11.1     OVERVIEW
      • 10.11.2     FINANCIALS
      • 10.11.3     PRODUCT PORTFOLIO
      • 10.11.4     KEY DEVELOPMENTS
      • 10.11.5     BUSINESS STRATEGY
      • 10.11.6     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     ORGAN-ON-A-CHIP GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($’000S)
      • TABLE 2     ORGAN-ON-A-CHIP UNITS SOLD BY CHIP COMPANIES AND SERVICE PROVIDERS (2018-2026)(NO.)
      • TABLE 3     ORGAN-ON-A-CHIP GLOBAL MARKET REVENUE, BY PRODUCT (2018-2026) ($’000S)
      • TABLE 4     CHIPS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($’000S)
      • TABLE 5     CHIPS GLOBAL MARKET REVENUE, BY ORGAN TYPE (2018-2026) ($’000S)
      • TABLE 6     LIVER-ON-A-CHIP GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($’000S)
      • TABLE 7     LUNG-ON-A-CHIP GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($’000S)
      • TABLE 8     KIDNEY-ON-A-CHIP GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($’000S)
      • TABLE 9     TUMOR-ON-A-CHIP GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($’000S)
      • TABLE 10     MULTI-ORGAN-ON-A-CHIP GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($’000S)
      • TABLE 11     OTHER CHIPS GLOBAL MARKET REVENUE, BY ORGAN TYPE (2018-2026) ($MN)
      • TABLE 12     OTHER ORGAN-ON-A-CHIP GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($’000S)
      • TABLE 13     SELECTED ORGAN-ON-A-CHIP COMPANIES (ORGAN MATRIX OR PRODUCT & SERVICE OFFERINGS)
      • TABLE 14     SERVICES GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($’000S)
      • TABLE 15     ORGAN-ON-A-CHIP GLOBAL MARKET REVENUE, BY MATERIAL TYPE (2018-2026) ($’000S)
      • TABLE 16     ORGAN-ON-A-CHIP GLOBAL MARKET REVENUE, BY APPLICATION (2018-2026) ($’000S)
      • TABLE 17     DRUG DISCOVERY GLOBAL MARKET REVENUE, BY REGION (2019-2026) ($’000S)
      • TABLE 18     TOXICITY SCREENING GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($’000S)
      • TABLE 19     PERSONALIZED MEDICINE GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($’000S)
      • TABLE 20     ORGAN-ON-A-CHIP GLOBAL MARKET REVENUE, BY END-USER (2018-2026) ($’000S)
      • TABLE 21     PHARMA BIOTECH GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($’000S)
      • TABLE 22     ACADEMICS AND RESEARCH INSTITUTES GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($’000S)
      • TABLE 23     OTHER INDUSTRIES GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($’000S)
      • TABLE 24     NORTH AMERICA ORGAN-ON-A-CHIP MARKET REVENUE, BY PRODUCT (2018-2026) ($’000S)
      • TABLE 25     NORTH AMERICA CHIPS MARKET REVENUE, BY ORGAN TYPE (2018-2026) ($’000S)
      • TABLE 26     NORTH AMERICA ORGAN-ON-A-CHIP MARKET REVENUE, BY APPLICATION (2018-2026) ($’000S)
      • TABLE 27     NORTH AMERICA ORGAN-ON-A-CHIP MARKET REVENUE, BY END-USER (2018-2026) ($’000S)
      • TABLE 28     EUROPE ORGAN-ON-A-CHIP MARKET REVENUE, BY PRODUCT (2018-2026) ($’000S)
      • TABLE 29     EUROPE CHIPS MARKET REVENUE, BY ORGAN TYPE (2018-2026) ($’000S)
      • TABLE 30     EUROPE ORGAN-ON-A-CHIP MARKET REVENUE, BY APPLICATION (2018-2026) ($’000S)
      • TABLE 31     EUROPE ORGAN-ON-A-CHIP MARKET REVENUE, BY END-USER (2018-2026) ($’000S)
      • TABLE 32     ASIA-PACIFIC ORGAN-ON-A-CHIP MARKET REVENUE, BY PRODUCT (2018-2026) ($’000S)
      • TABLE 33     ASIA-PACIFIC CHIPS MARKET REVENUE, BY ORGAN TYPE (2018-2026) ($’000S)
      • TABLE 34     ASIA-PACIFIC ORGAN-ON-A-CHIP MARKET REVENUE, BY APPLICATION (2018-2026) ($’000S)
      • TABLE 35     ASIA-PACIFIC ORGAN-ON-A-CHIP MARKET REVENUE, BY END-USER (2018-2026) ($’000S)
      • TABLE 36     REST OF THE WORLD ORGAN-ON-A-CHIP MARKET REVENUE, BY PRODUCT (2018-2026) ($’000S)
      • TABLE 37     REST OF THE WORLD CHIPS MARKET REVENUE, BY ORGAN TYPE (2018-2026) ($’000S)
      • TABLE 38     REST OF THE WORLD ORGAN-ON-A-CHIP MARKET REVENUE, BY APPLICATION (2018-2026) ($’000S)
      • TABLE 39     REST OF THE WORLD ORGAN-ON-A-CHIP MARKET REVENUE, BY END-USER (2018-2026) ($’000S)
      • TABLE 40     AGREEMENTS & COLLABORATIONS (2018-2020)
      • TABLE 41     NEW PRODUCT AND SERVICE LAUNCH (2018-2020)
      • TABLE 42     FUNDING (2018-2020)
      • TABLE 43     OTHERS (2018-2020)
      • TABLE 44     ORGANOVO HOLDINGS, INC. : TOTAL REVENUE AND R&D EXPENSES, (2017-2019) (Q3)($MN)
      • TABLE 45     ORGANOVO HOLDINGS, INC.: TOTAL REVENUE, BY SEGMENT, (2017-2019) (Q3) ($MN)

      LIST OF FIGURES

      • FIGURE 1     ORGAN-ON-A-CHIP GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($’000S)
      • FIGURE 2     RESEARCH METHODOLOGY: ORGAN-ON-A-CHIP GLOBAL MARKET
      • FIGURE 3     ORGAN-ON-A-CHIP GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
      • FIGURE 4     ORGAN-ON-A-CHIP GLOBAL MARKET: FORECASTING MODEL
      • FIGURE 5     ORGAN-ON-A-CHIP GLOBAL MARKET: MARKET BREAKDOWN AND DATA TRIANGULATION
      • FIGURE 6     ORGAN-ON-A-CHIP GLOBAL MARKET SEGMENTATION
      • FIGURE 7     MARKET DYNAMICS
      • FIGURE 8     ORGAN-ON-A-CHIP GLOBAL MARKET: PORTER’S FIVE FORCE ANALYSIS
      • FIGURE 9     ORGAN-ON-A-CHIP GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2019 (%)
      • FIGURE 10     ORGAN-ON-A-CHIO UNITS SOLD BY CHIP COMPANIES AND SERVICE PROVIDERS (2019 VS 2026) (NO’S)
      • FIGURE 11     ORGAN-ON-A-CHIP GLOBAL MARKET SHARE, BY PRODUCTS (2019 VS 2026) (%)
      • FIGURE 12     ORGAN-ON-A-CHIP PRODUCTS AND SERVICES COMPANIES
      • FIGURE 13     CHIPS GLOBAL MARKET SHARE, BY REGION (2019) (%)
      • FIGURE 14     CHIPS GLOBAL MARKET SHARE, BY ORGAN TYPE (2019 VS 2026) (%)
      • FIGURE 15     LIVER-ON-A-CHIP GLOBAL MARKET SHARE, BY REGION (2019) (%)
      • FIGURE 16     LUNG-ON-A-CHIP GLOBAL MARKET SHARE, BY REGION (2019) (%)
      • FIGURE 17     KIDNEY-ON-A-CHIP GLOBAL MARKET SHARE, BY REGION (2019) (%)
      • FIGURE 18     TUMOR-ON-A-CHIP GLOBAL MARKET SHARE, BY REGION (2019) (%)
      • FIGURE 19     MULTI-ORGAN-ON-A-CHIP GLOBAL MARKET SHARE, BY REGION (2019) (%)
      • FIGURE 20     OTHERS-ORGAN-ON-A-CHIP GLOBAL MARKET SHARE, BY REGION (2019) (%)
      • FIGURE 21     SELECTED COMPANIES AND THEIR PRODUCT & SERVICE OFFERING
      • FIGURE 22     SERVICES GLOBAL MARKET SHARE, BY REGION (2019) (%)
      • FIGURE 23     ORGAN-0N-A-CHIP GLOBAL MARKET SHARE, BY MATERIAL TYPE (2019 VS 2026) (%)
      • FIGURE 24     ORGAN-ON-A-CHIP GLOBAL MARKET SHARE, BY APPLICATION (2019 VS 2026) (%)
      • FIGURE 25     DRUG DISCOVERY GLOBAL MARKET SHARE, BY REGION (2019) (%)
      • FIGURE 26     TOXICITY SCREENING GLOBAL MARKET SHARE, BY REGION (2019) (%)
      • FIGURE 27     PERSONALIZED MEDICINE GLOBAL MARKET SHARE, BY REGION (2019) (%)
      • FIGURE 28     ORGAN-ON-A-CHIP GLOBAL MARKET SHARE, BY END-USER (2019 VS 2026) (%)
      • FIGURE 29     PHARMA BIOTECH GLOBAL MARKET SHARE, BY REGION (2019) (%)
      • FIGURE 30     ACADEMICS AND RESEARCH INSTITUTE GLOBAL MARKET SHARE, BY REGION (2019) (%)
      • FIGURE 31     OTHER INDUSTRIES GLOBAL MARKET SHARE, BY REGION (2019) (%)
      • FIGURE 32     NORTH AMERICA ORGAN-ON-A-CHIP MARKET SHARE BY PRODUCT (2019 VS 2026) (%)
      • FIGURE 33     NORTH AMERICA CHIPS MARKET SHARE, BY ORGAN TYPE (2019 VS 2026) (%)
      • FIGURE 34     NORTH AMERICA ORGAN-0N-A-CHIP MARKET SHARE, BY APPLICATION (2019 VS 2026) (%)
      • FIGURE 35     NORTH AMERICA ORGAN-0N-A-CHIP MARKET SHARE, BY END-USER (2019 VS 2026) (%)
      • FIGURE 36     EUROPE ORGAN-ON-A-CHIP MARKET SHARE BY PRODUCT (2019 VS 2026) (%)
      • FIGURE 37     EUROPE CHIPS MARKET SHARE, BY ORGAN TYPE (2019 VS 2026) (%)
      • FIGURE 38     EUROPE ORGAN-0N-A-CHIP MARKET SHARE, BY APPLICATION (2019 VS 2026) (%)
      • FIGURE 39     EUROPE ORGAN-0N-A-CHIP MARKET SHARE, BY END-USER (2019 VS 2026) (%)
      • FIGURE 40     ASIA-PACIFIC ORGAN-ON-A-CHIP MARKET SHARE BY PRODUCT (2019 VS 2026) (%)
      • FIGURE 41     ASIA-PACIFIC CHIPS MARKET SHARE, BY ORGAN TYPE (2019 VS 2026) (%)
      • FIGURE 42     ASIA-PACIFIC ORGAN-0N-A-CHIP MARKET SHARE, BY APPLICATION (2019 VS 2026) (%)
      • FIGURE 43     ASIA-PACIFIC ORGAN-0N-A-CHIP MARKET SHARE, BY END-USER (2019 VS 2026) (%)
      • FIGURE 44     REST OF THE WORLD ORGAN-ON-A-CHIP MARKET SHARE BY PRODUCT (2019 VS 2026) (%)
      • FIGURE 45     REST OF THE WORLD CHIPS MARKET SHARE, BY ORGAN TYPE (2019 VS 2026) (%)
      • FIGURE 46     REST OF THE WORLD ORGAN-0N-A-CHIP MARKET SHARE, BY APPLICATION (2019 VS 2026) (%)
      • FIGURE 47     REST OF THE WORLD ORGAN-0N-A-CHIP MARKET SHARE, BY END-USER (2019 VS 2026) (%)
      • FIGURE 48     KEY GROWTH STRATEGIES (2018-2020)
      • FIGURE 49     SWOT: ALVEOLIX AG
      • FIGURE 50     SWOT: CN BIO INNOVATIONS LTD.
      • FIGURE 51     SWOT: EMULATE, INC.
      • FIGURE 52     SWOT: HESPEROS, INC
      • FIGURE 53     SWOT: INSPHERO AG
      • FIGURE 54     SWOT: MIMETAS B. V.
      • FIGURE 55     SWOT: NORTIS, INC.
      • FIGURE 56     SWOT: ORGANOVO HOLDINGS, INC.
      • FIGURE 57     SWOT: SYNVIVO, INC.
      • FIGURE 58     SWOT: TARA BIOSYSTEMS, INC
      • FIGURE 59     SWOT: TISSUSE GMBH

      LIST OF COMPANIES MENTIONED IN THE REPORT

      • 1     4DESGIN BIOSCIENCES
      • 2     AIM BIOTECH PTE. LTD.
      • 3     ALTIS BIOSYSTEMS, INC
      • 4     ALVEOLIX AG
      • 5     ANANDA DEVICES
      • 6     ARACARI BIOSCIENCES INC.
      • 7     AXOSIM, INC.
      • 8     BEONCHIP S.L.
      • 9     BIO 4DESIGN BIOSCIENCES
      • 10     BIO IVT
      • 11     BIOMIMX SRL
      • 12     BIOND SOLUTIONS B.V.
      • 13     CN BIO INNOVATIONS, LTD.
      • 14     DRAPER LABORATORIES
      • 15     ELSE KOOI LAB.
      • 16     EMULATE, INC.
      • 17     EPISKIN SA
      • 18     HESPEROS INC.
      • 19     HUREL CORPORATION
      • 20     INSPHERO AG
      • 21     JIKSAK BIOENGINEERING, INC.
      • 22     KIRKSTALL LTD
      • 23     MESOBIOTECH
      • 24     MICROBRAIN BT SAS
      • 25     MICRONIT MICRO TECHNOLOGIES B.V.
      • 26     MIMETAS B.V.
      • 27     MYRIAMED GMBH
      • 28     NORTIS, INC.
      • 29     ORGANOVO HOLDINGS, INC
      • 30     QUORUM TECHNOLOGIES INC.
      • 31     STEMONIX INC.
      • 32     SYNVIVO,INC.
      • 33     TARA BIOSYSTEMS, INC.,
      • 34     TISSUE DYNAMICS LTD.
      • 35     TISSUSE GMBH
      • 36     XONA MICROFLUIDICS, INC.